A Phase 3 interventional study of Tislelizumab and Paclitaxel in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by BeiGene. Completed at 104 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.
Sponsored by BeiGene · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma — 13 open to participants now, 15 under way, 1 of them phase 3. tislelizumab · Esophageal Squamous Cell Carcinoma.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 1st registered.
679 studies on the registry are indexed under Esophageal Squamous Cell Carcinoma; 270 are open to participants now.
Browse Esophageal Squamous Cell Carcinoma studies →13 of the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma are open now, in 4 countries. Recruiting first, the newest first:
BeOne Medicines · Sites in Japan
Ages 18+
BeOne Medicines · Sites in United States
Ages 18+
Ming-Yu Lien · Sites in Taiwan
Ages 20+
Shanghai Zhongshan Hospital · Sites in China
Ages 18+
Sichuan University · Sites in China
Ages 18–75
By country, each count listing its studies:
tislelizumab: first FDA approval 2024 (TEVIMBRA), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 181 Esophageal Squamous Cell Carcinoma studies recruiting now, 84 (46%) set no upper age limit and 76 (42%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 17 · Phase 3 4 · Phase 4 1
First in 2018; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 512 is above the median of 64 across 565 interventional studies indexed under Esophageal Squamous Cell Carcinoma.
Median enrollment 50 across the 23 interventional studies. Of the 6 that completed or were terminated, 5 (83%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 23 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines: 2 open now, 2 under way, none of them phase 3. Of 8 finished, 6 (75%) have results posted.
Among the 10 studies in Esophageal Squamous Cell Carcinoma by BeOne Medicines, this one is the 2nd largest by enrollment, is one of 2 that started in 2018, is one of 3 in phase 3, and was the 1st registered.
BeOne Medicines’s Esophageal Squamous Cell Carcinoma studies by the year they started, since 2017.
1 of the studies testing tislelizumab in Esophageal Squamous Cell Carcinoma that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07317609Shanghai Zhongshan HospitalNeoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02) | 2027-09-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies testing tislelizumab in Esophageal Squamous Cell Carcinoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among BeOne Medicines’s 10 in Esophageal Squamous Cell Carcinoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
Key Inclusion Criteria:
Key Exclusion Criteria:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Tislelizumab on Day 1, given every 21 days
Drug: Tislelizumab
Paclitaxel on Day 1, given every 21 days or on a weekly schedule; OR Docetaxel on Day 1, given every 21 days; OR Irinotecan on Days 1 and 8, given every 21 days
Drug: Paclitaxel · Drug: Docetaxel · Drug: Irinotecan
200 mg administered intravenously (IV)
Also known as: BGB-A317
135-175 mg /m² administered IV , or 80-100 mg/m\^2 administered IV according to local guidelines for standard of care
75 mg/m\^2 administered IV or 70 mg/m\^2 IV in Japan
125 mg/m\^2 administered IV
Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set
OS is defined as the length of time from the date of randomization until the date of death due to any cause in all randomized participants
Time frame: Approximately 2 years and 10 months from date of first randomization
Overall Survival (OS) in the PDL-1 Positive Analysis Set
OS is defined as the time from the date of randomization until the date of death due to any cause in the PD-L1 positive population, defined as vCPS ≥10%.
Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Objective Response Rate (ORR) in the ITT Analysis Set
ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets
ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1;
Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Progression-free Survival (PFS) in the ITT Analysis Set
PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the ITT analysis set
Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set
PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the PDL-1 Positive Analysis Set
Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Duration of Response (DOR) in the ITT Analysis Set
DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first
Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Duration of Response (DOR) in the PDL-1 Positive Analysis Set.
DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first
Time frame: Through End-of-Trial Analysis data cutoff date of 28-Dec-2022 (up to approximately 5 years)
Health-Related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C-30) in the ITT Analysis Set
Mean change from baseline in EORTC QLQ-C30 index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes
Time frame: Baseline to Cycle 6 (21 days per cycle)
HRQoL as Assessed by EORTC QLQ-C30 in the PDL-1 Positive Analysis Set
Mean change from baseline in EORTC QLQ-C30 Index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes
Time frame: Baseline to Cycle 6 (21 days per cycle)
HRQoL as Assessed by EORTC QLQ-Oesophagus Cancer Module (EORTC QLQ-OES18) Reported in ITT Analysis Set
Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 (21 days per cycle)
HRQoL as Assessed by EORTC QLQ-OES18) in the PDL-1 Positive Analysis Set.
Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 (21 days per cycle)
HRQoL as Assessed by European Quality of Life 5-Dimensions 5-Level Questionnaire (EQ-5D-5L) in the ITT Analysis Set
Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 (21 days per cycle)
HRQoL as Assessed by EQ-5D-5L in the PD-L1 Positive Analysis Set
Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
Time frame: Baseline to Cycle 6 (21 days per cycle)
Number of Participants Experiencing Adverse Events (AEs)
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs
Time frame: From the first dose date to 30 days after the last dose date; up to approximately 4 years and 11 months
This study was conducted at 132 study centers in Mainland China, Taiwan, United States, France, Italy, Germany, Spain, Japan, South Korea, Belgium and the United Kingdom.
| Milestone | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Started | 256 | 256 |
| Treated | 255 | 240 |
| Completed | 0 | 0 |
| Not completed | 256 | 256 |
| Withdrew: Death | 233 | 233 |
| Withdrew: Sponsor decision | 17 | 6 |
| Withdrew: Withdrawal by subject | 5 | 14 |
| Withdrew: Lost to follow-up | 1 | 3 |
OS is defined as the length of time from the date of randomization until the date of death due to any cause in all randomized participants
| Months | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Overall Survival (OS) in the Intent-to-Treat (ITT) Analysis Set | 8.6 (7.5 to 10.4) | 6.3 (5.3 to 7.0) |
OS is defined as the time from the date of randomization until the date of death due to any cause in the PD-L1 positive population, defined as vCPS ≥10%.
| Months | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Overall Survival (OS) in the PDL-1 Positive Analysis Set | 10.2 (8.5 to 14.5) | 5.1 (3.8 to 8.2) |
ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1;
| Percentage of Participants | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Objective Response Rate (ORR) in the ITT Analysis Set | 20.3 (15.6 to 25.8) | 9.8 (6.4 to 14.1) |
ORR is defined as the percentage of participants who had complete response (CR) or partial response (PR) as assessed by the investigator per RECIST v1.1;
| Percentage of Participants | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Overall Response Rate (ORR) in the PD-L1 Positive Analysis Sets | 26.3 (17 to 37.3) | 11.3 (4.7 to 21.9) |
PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the ITT analysis set
| Months | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) in the ITT Analysis Set | 1.6 (1.4 to 2.7) | 2.1 (1.5 to 2.7) |
PFS is defined as the time from the date of randomization to the date of first documentation of disease progression assessed by the investigator per RECIST v1.1 or death, whichever occurs first; reported for the PDL-1 Positive Analysis Set
| Months | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Progression-free Survival (PFS) in the PDL-1 Positive Analysis Set | 2.7 (1.5 to 4.2) | 2.3 (1.4 to 3.0) |
DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first
| Months | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Duration of Response (DOR) in the ITT Analysis Set | 7.1 (4.1 to 11.3) | 4.0 (2.1 to 8.2) |
DOR is defined as the time from the first determination of an objective response until the first documentation of progression as assessed by the investigator per RECIST v1.1, or death, whichever comes first
| Months | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Duration of Response (DOR) in the PDL-1 Positive Analysis Set. | 7.1 (2.9 to 13.2) | 5.7 (1.2 to NA) |
Mean change from baseline in EORTC QLQ-C30 index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes
| Score on a scale | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Baseline | 16.2 ± 12.28 | 18.3 ± 13.86 |
| Change at Cycle 6 | 0.2 ± 8.28 | 4.8 ± 9.38 |
Mean change from baseline in EORTC QLQ-C30 Index score. The EORTC QLQ-C30 v3.0 is a questionnaire that assesses quality of life of cancer participants. It includes global health status and quality of life questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes
| Score on a scale | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Baseline | 16.8 ± 10.96 | 18.8 ± 12.02 |
| Change at Cycle 6 | 0.5 ± 7.39 | 0.5 ± 4.86 |
Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Baseline | 14.7 ± 11.81 | 16.3 ± 13.20 |
| Change at Cycle 6 | -0.6 ± 8.63 | 3.0 ± 12.05 |
Mean change from baseline in EORTC QLQ-OES18 index score. The EORTC QLQ-OES18 is a questionnaire that assesses overall symptoms in esophageal cancer participants. It includes questions related to overall health in which participants respond based on a 7-point scale, where 1 is very poor and 7 is excellent. Raw scores are transformed into a 0 to 100 scale via linear transformation. A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Baseline | 16.5 ± 12.69 | 18.1 ± 12.21 |
| Change at Cycle 6 | -0.9 ± 7.45 | -2.9 ± 5.16 |
Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Baseline | 73.7 ± 17.05 | 72.5 ± 18.13 |
| Change at Cycle 6 | -0.6 ± 14.81 | -5.9 ± 16.34 |
Mean change from baseline in EQ-5D-5L visual acuity score (VAS). The EQ-5D-5L measures health outcomes using a VAS to record a participant's self-rated health on a scale from 0 to 100, where 100 is 'the best health you can imagine' and 0 is 'the worst health you can imagine.' A higher score indicates better health outcomes.
| Score on a scale | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Baseline | 74.1 ± 14.84 | 70.5 ± 18.40 |
| Change at Cycle 6 | -0.5 ± 17.59 | 4.4 ± 12.82 |
Number of participants with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs), which includes laboratory tests, physical exams, electrocardiogram results and vital signs
| Participants | Tislelizumab | Investigator Chosen Chemotherapy |
|---|---|---|
| Number of participants with TEAEs | 245 | 236 |
| Number of participants with SAEs | 109 | 106 |
Collected over All-cause mortality and adverse events (AEs): up to approximately 4 years and 11 months. Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tislelizumab | 233/256 (91%) | 109/255 (42.7%) | 232/255 (91%) |
| Investigator Chosen Chemotherapy (ICC) | 233/256 (91%) | 106/240 (44.2%) | 231/240 (96.3%) |
| Event | Tislelizumab | Investigator Chosen Chemotherapy (ICC) |
|---|---|---|
| PneumoniaInfections and infestations | 19/255 | 17/240 |
| DysphagiaGastrointestinal disorders | 13/255 | 4/240 |
| Neutrophil count decreasedInvestigations | 0/255 | 10/240 |
| Febrile neutropeniaBlood and lymphatic system disorders | 0/255 | 8/240 |
| DiarrhoeaGastrointestinal disorders | 0/255 | 8/240 |
| White blood cell count decreasedInvestigations | 0/255 | 8/240 |
| Decreased appetiteMetabolism and nutrition disorders | 1/255 | 6/240 |
| Oesophageal obstructionGastrointestinal disorders | 5/255 | 1/240 |
| PneumonitisRespiratory, thoracic and mediastinal disorders | 5/255 | 2/240 |
| LeukopeniaBlood and lymphatic system disorders | 0/255 | 4/240 |
| Event | Tislelizumab | Investigator Chosen Chemotherapy (ICC) |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 80/255 | 109/240 |
| White blood cell count decreasedInvestigations | 11/255 | 95/240 |
| Neutrophil count decreasedInvestigations | 6/255 | 88/240 |
| Decreased appetiteMetabolism and nutrition disorders | 42/255 | 80/240 |
| DiarrhoeaGastrointestinal disorders | 32/255 | 75/240 |
| NauseaGastrointestinal disorders | 37/255 | 72/240 |
| Weight decreasedInvestigations | 62/255 | 45/240 |
| VomitingGastrointestinal disorders | 27/255 | 48/240 |
| ConstipationGastrointestinal disorders | 41/255 | 45/240 |
| FatigueGeneral disorders | 33/255 | 42/240 |
| Age, Continuous(years) | Tislelizumab | Investigator Chosen Chemotherapy | Total |
|---|---|---|---|
| Mean | 61.8 ± 8.41 | 61.8 ± 8.02 | 61.8 ± 8.21 |
| Sex: Female, Male(Participants) | Tislelizumab | Investigator Chosen Chemotherapy | Total |
|---|---|---|---|
| Female | 39 | 41 | 80 |
| Male | 217 | 215 | 432 |
| Ethnicity (NIH/OMB)(Participants) | Tislelizumab | Investigator Chosen Chemotherapy | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 2 | 4 |
| Not Hispanic or Latino | 252 | 252 | 504 |
| Unknown or Not Reported | 2 | 2 | 4 |
| Race/Ethnicity, Customized(Participants) | Tislelizumab | Investigator Chosen Chemotherapy | Total |
|---|---|---|---|
| Race — Asian | 201 | 207 | 408 |
| Race — White or Caucasian | 53 | 44 | 97 |
| Race — Not Reported | 1 | 0 | 1 |
| Race — Unknown | 1 | 2 | 3 |
| Race — Black or African American | 0 | 2 | 2 |
| Race — Other | 0 | 1 | 1 |
| Eastern Cooperative Oncology Group (ECOG) Performance Status Score(Participants) | Tislelizumab | Investigator Chosen Chemotherapy | Total |
|---|---|---|---|
| 0 | 66 | 61 | 127 |
| 1 | 190 | 195 | 385 |
| PD-L1 Expression Status(Participants) | Tislelizumab | Investigator Chosen Chemotherapy | Total |
|---|---|---|---|
| vCPS >= 10% | 80 | 62 | 142 |
| vCPS < 10% | 100 | 122 | 222 |
| Missing | 76 | 72 | 148 |
Showing the first 100 of 104 sites across 11 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jan 2018 to primary completion in Dec 2020, 34 months.
Results were first posted in Dec 2023, 3 years after primary completion. A results delay was requested in Nov 2021.
Of 44 phase 3 interventional studies under Esophageal Squamous Cell Carcinoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 76. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tislelizumab
Esophageal Squamous Cell Carcinoma →